EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies


European Journal of Pharmaceutics and Biopharmaceutics 74(2): 290-297
RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies
The purpose of this study was to investigate the human nasal epithelial cell line RPMI 2650 regarding its usefulness as in vitro model for drug permeation studies. Particularly, the influence of the air-liquid interface in culture and coculture with human nasal fibroblasts (HNF) on the differentiation and permeation barrier properties of the cell layer was examined. In addition to a non-contact coculture, we developed a three-dimensional construct of the human nasal mucosa composed of a collagen matrix with embedded HNF, covered by a RPMI 2650 epithelial cell layer. Microscopic examination as well as measurement of the transepithelial electrical resistance and permeation experiments showed the importance of cultivation at the air-liquid interface. Permeation studies were performed using a paracellular marker (sodium fluorescein), a transcellular marker (propranolol-HCl) and a model substance with high molecular weight (FITC-dextran, MW 4000). The epithelial model showed an organotypic permeation barrier for paracellular, transcellular and high MW permeation. Three-dimensional reconstructed human nasal mucosa showed four- to fivefold higher permeation coefficients. Regardless of the limits of these models, both offer promise to evaluate passive drug permeation through the nasal mucosa.


Accession: 055338605

PMID: 19733661

DOI: 10.1016/j.ejpb.2009.08.008



Related references

The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharmaceutical Research 32(2): 665-679, 2015

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics 107: 223-233, 2016

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. Journal of Pharmaceutical Sciences 97(3): 1165-1178, 2007

Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics 508(1-2): 22-33, 2016

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology 64(11): 1621-1630, 2013

Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 33(4): 194-198, 1995

The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clinical and Experimental Allergy 35(6): 811-819, 2005

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 65(3): 395-406, 2012

Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 21(5): -, 2016

Roles of epidermal growth factor receptor signaling pathway on cultured human nasal epithelial cells RPMI-2650. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44(3): 203-208, 2011